Efficient Optimization Strategy for Marginal Hits Active Against abl Tyrosine Kinases

Publisher： Bentham Science Publishers

E-ISSN： 1875-6220|1|3|201-210

ISSN： 1570-1638

Source： Current Drug Discovery Technologies, Vol.1, Iss.3, 2004-10, pp. : 201-210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dual Inhibitors of Src and Abl Tyrosine Kinases

By  

Drug Design Reviews - Online, Vol. 1, Iss. 3, 2004-07 ,pp. : 203-214

Bentham Science Publishers

Access to resources Recommend Favorite

Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders

By  

Current Drug Targets, Vol. 8, Iss. 2, 2007-02 ,pp. : 205-216

Bentham Science Publishers

Access to resources Recommend Favorite

Last Findings on Dual Inhibitors of Abl and Src Tyrosine-Kinases

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 2, 2007-02 ,pp. : 191-201

Bentham Science Publishers

Access to resources Recommend Favorite

Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB family of Receptor Tyrosine Kinases: First Step in the Development of Therapeutic Antibody/Liposomal Anticancer Drug Combinations

By  

Letters in Drug Design & Discovery, Vol. 3, Iss. 10, 2006-12 ,pp. : 704-713

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting tyrosine-kinases in ovarian cancer

By Morotti Matteo   Becker Christian M   Menada Mario Valenzano   Ferrero Simone  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1265-1279

Informa Healthcare

Access to resources Recommend Favorite